Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset
HRS-5346 Is In Phase II In China
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
